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Abstract
Background: Okadaic acid (OA), a toxin produced by several dinoflagellate species is responsible for frequent food
poisonings associated to shellfish consumption. Although several studies have documented the OA effects on
different processes such as cell transformation, apoptosis, DNA repair or embryogenesis, the molecular mechanistic
basis for these and other effects is not completely understood and the number of controversial data on OA is
increasing in the literature.
Results: In this study, we used suppression subtractive hybridization in SHSY5Y cells to identify genes that are
differentially expressed after OA exposure for different times (3, 24 and 48 h). A total of 247 subtracted clones
which shared high homology with known genes were isolated. Among these, 5 specific genes associated with
cytoskeleton and neurotransmission processes (NEFM, TUBB, SEPT7, SYT4 and NPY) were selected to confirm their
expression levels by real-time PCR. Significant down-regulation of these genes was obtained at the short term (3
and 24 h OA exposure), excepting for NEFM, but their expression was similar to the controls at 48 h.
Conclusions: From all the obtained genes, 114 genes were up-regulated and 133 were down-regulated. Based on
the NCBI GenBank and Gene Ontology databases, most of these genes are involved in relevant cell functions such
as metabolism, transport, translation, signal transduction and cell cycle. After quantitative PCR analysis, the
observed underexpression of the selected genes could underlie the previously reported OA-induced cytoskeleton
disruption, neurotransmission alterations and in vivo neurotoxic effects. The basal expression levels obtained at 48 h
suggested that surviving cells were able to recover from OA-caused gene expression alterations.
Background
Okadaic acid (OA) is a marine toxin produced by sev-
eral dinoflagellate species. It was firstly isolated from the
black sponge Halichondria okadai [1] and is frequently
found in several types of molluscs usual in the human
diet as those from Mytilus or Ostrea genus. The inges-
tion of OA-contaminated shellfish results in a syndrome
known as diarrhoeic shellfishp o i s o n i n g( D S P )w h i c hi s
characterized by severe gastrointestinal symptoms
including nauseas, vomit, diarrhoea and abdominal ache
[2]. Although fatalities associated with DSP-contami-
nated shellfish have not been reported, this intoxication
has become a serious problem for public health and for
the economy of aquaculture industries in several parts
of the world [3].
OA was found to be a very potent tumour promoter
in two-stage carcinogenesis experiments in vivo invol-
ving mouse skin [4] or mucosa of the rat glandular sto-
mach [5]. OA was also reported to induce different
genotoxic, cytotoxic, and embryotoxic effects such as
micronuclei [6-8], oxidative DNA damage [9,10], DNA
strand breaks and alterations in DNA repair [11], mito-
tic spindle alterations [12,13], apoptosis [14,15], cell
cycle disruptions [15,16], anomalies of the embryonic
development [17] and teratogenicity [18]. Besides,
despite the fact that DSP toxins are not classified as
neurotoxins [19], some previous studies have already
reported neurotoxic effects induced by OA including
neuronal apoptosis and cytoskeleton alterations [20,21],
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in rodents [23].
On the basis on these and other previous studies, OA
represents other potential threats to human health
besides DSP, even at concentrations within the nanomo-
lar range. It is well-known that OA can inhibit specifi-
cally the serine/threonine protein phosphatases 1 (PP1)
and 2A (PP2A) [24]; the number of physiological pro-
cesses in which those phosphatases are involved is
immense, including regulation of glycogen metabolism
and coordination of the cell cycle and gene expression
[25]. So this role of phosphatase inhibition by OA could
explain most of the cell effects induced by this toxin
[26]. However the number of controversial data in the
literature continues increasing and further investigations
on biochemical and molecular OA action mechanisms
are required since the fact that non-phosphatase targets
for OA are not known does not mean that they do not
exist [3]. In fact, the existence of OA binding proteins
other than phosphatases was demonstrated in several
marine organisms [27,28].
In this study, a suppression subtractive hybridization
(SSH) approach was used to identify genes differentially
expressed in SHSY5Y cells in response to OA exposure
at different times (3, 24 and 48 h). Sequences obtained
by SSH were used to search for homology/identity to
nucleotide and protein databases. Furthermore, differen-
tial expression patterns of 5 selected genes were also
studied in OA-treated SHSY5Y cells at 3, 24 and 48 h
by real-time PCR.
Methods
Cell culture and OA treatment
SHSY5Y cells (human neuroblastoma cell line) were
obtained from the European Collection of Cell Cultures
and cultured in nutrient mixture EMEM/F12 (1:1) med-
ium with 1% non-essential aminoacids, 1% antibiotic
and antimycotic solution and supplemented with 10%
heat-inactivated foetal bovine serum, all from Invitrogen
(Barcelona, Spain). The cells were incubated in a humi-
dified atmosphere with 5% CO2 at 37°C. OA (CAS No.
78111-17-8) was purchased from Sigma-Aldrich Co.
(Madrid, Spain) and dissolved in DMSO prior use.
Flasks with approximately 90% of confluence and 4 ×
10
6 cells were chosen for the experiments. For the treat-
ments, cells were incubated at 37°C for 3, 24 or 48 h in
the presence of OA (100 nM) or the control dimethyl-
sulfoxide (DMSO) at 1% of final volume.
Total RNA isolation and cDNA synthesis for SSH
After OA treatments, total RNA was isolated from
SHSY5Y cells with TRIZOL
® reagent (Invitrogen,
Madrid, Spain) following the manufacturer’si n s t r u c -
tions, and then dissolved in nuclease-free water. RNA
was quantified and quality checked using the NANO-
DROP™ 1000 spectrophotometer (Thermo Scientific,
Madrid, Spain). One microgram of total RNA from each
s a m p l ew a su s e da st e m p l a t et os y n t h e s i z et h ef i r s t
strand cDNA with the SMART™ PCR cDNA Synthesis
Kit (Clontech, Madrid, Spain), a method for producing
high quality cDNA from a low amount of starting mate-
rial [29]. The double stranded cDNA was amplified with
the same Kit according to the manufacturer’s protocol.
Construction of subtracted cDNA libraries
SSH was carried out with the PCR-Select™ cDNA sub-
traction kit (Clontech, Madrid, Spain), as described by
the manufacturer. Briefly, the double stranded cDNAs
obtained from the step described above were digested
with the restriction enzyme RsaIt oo b t a i nb l u n t - e n d s
that are necessary for adaptor ligation. cDNA subtrac-
tion was carried out in two directions for the different
exposure times. The forward subtracted libraries were
made with the control cells cultured for 3, 24 or 48 h as
the driver and OA-exposed cells (also cultured for 3, 24
or 48 h) as the tester. These forward reaction libraries
were designed to produce clones that are overexpressed
or up-regulated in OA-treated cells. The reverse
libraries were made in the same way, but in this case
the adapter ligated cDNA from OA-exposed cells were
the driver and control cells were the tester. The reverse
reaction library was designed to produce clones under-
expressed or down-regulated in OA-treated cells. In
either case the driver cDNA was added in excess during
each hybridization to remove common cDNAs by hybrid
selection and leaving overexpressed and novel tester
cDNA to be recovered and cloned. The subtracted
cDNA fragments were then inserted into yT&A
® clon-
ing vector, transformed into Escherichia coli ECOS707
(strain JM109) competent cells, and plated on LB agar
plates containing 100 μg/ml ampicillin, 100 μlI P T G
(100 mM) and 20 μl X-gal (50 mg/ml). The yT&A
®
cloning vector and the E. coli ECOS707 competent cells
were purchased from Yeastern Biotech. Co., Ltd., (Tai-
pei, Taiwan). From the six libraries, a total of 384 white
recombinant colonies (corresponding to four 96-well
plates) were picked.
Sequencing of the subtracted cDNA clones and
bioinformatics analysis
Sequencing of all the cDNA clones from the six SSH
libraries was carried out using the BigDye
® Terminator
v3.1 (Applied Biosystems) and an AB3730 sequencer
(Applied Biosystems) at Secugen (Madrid, Spain). After
excluding redundant and false-positive sequences,
nucleic acid homology searches were performed against
nucleotide databases at the National Center for Biotech-
nology Information (NCBI) using the Basic Local
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www.ncbi.nlm.nih.gov/BLAST to provide gene annota-
tion. Homologies that showed identities over 60% and
E-values of less than 1 × E
-10 with more than 100
nucleotides were considered to be significant. The dif-
ferentially expressed genes identified through expression
analysis were classified according to the definition of
Gene Ontology (GO) http://www.geneontology.org/
related to the aspects of biological and molecular
function.
Differential screening of the subtracted libraries
With the aim of checking the level of background corre-
sponding to common mRNAs in reverse and forward
libraries we carried out a differential screening of sub-
tracted libraries using the PCR select differentially
screening kit (Clontech, Madrid, Spain), following the
manufacturer’s instructions. Briefly, PCR products from
positive colonies were immobilized in nylon membranes
and hybridized with forward- and reverse- probes.
Those clones representing mRNAs truly differentially
expressed should hybridize only with its corresponding
forward-probe. Prior to hybridization forward- and
reverse-probes were digested for removing adaptors.
More than 90% of the clones tested resulted positive for
the virtual Northern analysis (data not shown).
Simple gene set enrichment analysis
A simple gene set enrichment analysis was performed
using FatiGO tool (Babelomics 4.2 suite, http://babelo-
mics.bioinfo.cipf.es/). FatiGO takes two lists of genes
and convert them into two lists of GO annotations.
Then a Fisher’s exact test for 2 × 2 contingency tables is
used to check for significant over-representation of GO
annotations in one of the sets with respect to the other
one. Multiple test correctioni sa p p l i e da sam e a s u r eo f
control for false positives. In our case, we conducted
two single gene set enrichment analysis for KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathways
comparing our set genes from forward and reverse
libraries with the rest of annotations in human genome
(additional files 1 and 2).
Quantitative PCR
Five EST identified from SSH were chosen for their spe-
cific analysis with real-time PCR. First strand synthesis
was performed on 100 ng of the same total RNA sam-
ples prepared for SSH from OA-treated and control
SHSY5Y cells (for 3, 24 and 48 h) using the Transcrip-
tor First Strand cDNA Synthesis Kit (Roche). Oligonu-
cleotide primers were designed based on the EST
sequences determined for candidate differentially
expressed genes using the web tool Universal ProbeLi-
brary (Roche) (Table 1). Quantitative PCR was run in
triplicate using LightCycler
® SYBR green I Master Kit
(Roche) and LightCycler
® 480 Real-time PCR Detection
System (Roche). The PCR conditions were 95°C for 10
s, 60°C for 10 s, and 72°C for 5 s, for 45 cycles, and
final extension of 5 min. A subsequent melting tempera-
ture curve of the amplicon was performed. Efficiency of
target amplification was optimised prior to running
samples for each of the five primer pairs by assaying
four primer concentrations (200, 150, 100 and 50 nM).
The number of amplification steps required to reach the
threshold cycle number (Ct) was computed using Light-
Cycler software 1.5.0 (Roche). Constant Ct values were
observed at a 100 nM final primer concentration for
each of the primer pairs. Ct values were calculated from
the standard curve, entered into the qBasePlus software
[30] and used to generate an input file for genNorm
software v3.5 [31]. GenNorm determined the most
stable reference genes out of the panel of candidate
genes using expression stability analysis by pair wise
correlations. Following the results of the genNorm, TPR,
ACTB and NM23A genes were selected and run sepa-
rately in all experiments under the same conditions.
Normalised cDNA levels of each gene were calculated
using qBasePlus [30] once the most stable reference
genes were determined. The expression levels of each
gene of the 3 h libraries were normalised against both
TPR and ACTB, 24 h libraries genes were normalized
against both ACTB and NM23A, and 48 h libraries
genes were normalized against both TPR and NM23A.
Statistical analysis
Experimental data were expressed as mean ± standard
error. Statistical analyses between groups were carried
out using Student’s t-test and a P-value of < 0.05 was
Table 1 Primers used in real-time PCR analysis
Genes Primers (5’-3’) Product (bp)
NEFM TGCCGGCTACATAGAGAAGG 62
TCTCCGCCTCAATCTCCTTA
TUBB CCCTCTGTGTAGTGGCCTTT 68
CCAGACAACTTTGTATTTGGTCA
SEPT7 CACAATGTTCACCATTTTTCAAC 82
TCATTGAAGTTAATGGCAAAAGG
SYT4 AAAGTTGTAAGGGGCCAATTC 70
ACCTCAGCTGCTACCACCAT
NPY CGCTGCGACACTACATCAAC 62
CTCTGGGCTGGATCGTTTT
TPR CCACCGAGCGAGGTGATA 67
AGAAGAAAGGCGAAGACCAGT
ACTB AAGTCCCTTGCCATCCTAAAA 91
ATGCTATCACCTCCCCTGTG
NM23A ACATCCATTTCCCCTCCTTC 92
AGCTTCCCTCCAAACTATGATG
Valdiglesias et al. BMC Genomics 2012, 13:46
http://www.biomedcentral.com/1471-2164/13/46
Page 3 of 14considered significant. Statistical analysis was performed
using the SPSS for Windows statistical package (version
16.0).
Results and Discussion
The human SHSY5Y neuroblastoma cell line has been
extensively used as a neuron model in many neurobiolo-
gical, neurochemical, and neurotoxicological studies
[32-37]. In the present study, we investigated the effects
of OA, the main DSP toxin, on gene expression of
SHSY5Y cells after 3, 24 and 48 h treatments.
Identification of genes with different transcript levels in
OA-exposed SHSY5Y cells
For each exposure time 2 subtracted cDNA libraries (one
forward and one reverse) were obtained. We isolated a
total of 114 subtracted clones from the forward libraries
(Table 2) and 133 from the reverse libraries (Table 3).
These characterized genes were associated with var-
ious functions including metabolism, signal transduc-
tion, and cytoskeleton and cell adhesion. The genes
altered after the 3 h OA treatment were related to elec-
tron transport chain and redox homeostasis, signal
transduction, metabolism, transcription, translation, cell
cycle and apoptosis, and cytoskeleton and cell adhesion
(Figure 1). Most of these genes are apparently involved
in metabolism including electron transport chain and
redox homeostasis. A few studies have previously
reported the OA effects on the cell metabolism. Cable et
al. [38] observed that OA affected the heme metabolism
of human hepatic cell lines. Also, Shisheva and Shechter
[39] showed that OA mimicked some of insulin bioef-
fects stimulating the glucose and lipid metabolism in rat
adipocytes, and Tanti et al. [40] found that glycolysis
was stimulated and glucose transport was increased
after OA treatment in mouse skeletal muscle. More
recently, another study showed that OA depressed the
metabolic rate of rat hepatocytes and changed glucose
uptake in these cells [41]. Related to electron transport
chain, OA was previously found to induce alterations in
mitochondrial membrane potential [42] and increased
oxidative stress in the rat brain after intracerebroventri-
cular injection [43], and in different cell types in vitro
[10,44]. The altered expression levels in genes related to
cell metabolism and electron transport chain found in
this study could help to explain the effects described in
all these works. Besides, 8% of the genes altered after
the 3 h OA treatment were related to cellular transport
processes. OA was previously found to interfere in the
secretion of newly synthesized proteins and exocytosis
in rats [45]; both effects could be related to the expres-
sion alterations found in the present study.
When cells were treated with OA for 24 h, the
obtained genes were also categorized into different
groups including translation, signal transduction, elec-
tron transport chain and redox homeostasis, metabo-
lism, cell cycle and apoptosis, transcription and
nuclear specific proteins, transport, and cytoskeleton
and cell adhesion (Figure 2). Similar to the 3 h OA
treatment, an important number of these genes are
involved in metabolism including electron transport
chain, but also a great percentage of genes related to
translation were observed. The expression alterations
found in the genes involved in processes of translation
and transcription might be related to the previously
reported OA-induced inhibition of protein synthesis
[45,46].
Among the genes altered after the 48 h OA treatment,
most were related to signal transduction, translation,
cell cycle and apoptosis, electron transport chain and
redox homeostasis, metabolism, cytoskeleton and cell
adhesion, transcription and nuclear specific proteins,
and transport (Figure 3). Fewer genes related to metabo-
lism and transcription were found altered at 48 h, but
similarly to 24 h an important percentage of altered
genes are involved in cell cycle and apoptosis. In
another previous study, the gene expression alterations
in mouse BALB/c3T3 cells after different OA treatment
times (from 4 h to 24 days, 7.8 ng/ml) were evaluated
by microarray analysis, and a total of 177 differentially
expressed genes were identified [47]. The authors
focused this study on the 31 genes found to be function-
ally involved in cell growth and/or maintenance, and
observed that numerous genes associated with cell pro-
liferation and cell cycle progression were down-regu-
lated after OA treatment. Several genes related to
apoptotic processes, some of them involved in the mito-
chondrial pathway of apoptosis, were also found to be
altered. On the basis of their results, they concluded
that multiple molecular pathways could be involved in
OA-induced proliferation inhibition and apoptosis in
these cells [47].
Two simple gene set enrichment analysis were per-
formed using FatiGO tool to find which cellular KEGG
pathways could be affected by OA exposure in SHSY5Y
cells. The results obtained for the forward libraries
revealed a total of 3 KEGG pathways altered: oocyte
meiosis (hsa04114, adjusted p-value = 0.003), Parkin-
son’s disease (hsa05012, adjusted p-value = 0.035), and
cell cycle (hsa04110, adjusted p-value = 0.003). The
genes corresponding to reverse libraries were signifi-
cantly associated with KEGG pathways related to: glyco-
lysis (hsa00010, adjusted p-value = 0.044), oxidative
phosphorylation (hsa00190, adjusted p-value = 0.012),
Vibrio cholerae infection (hsa05110, adjusted p-value =
0.044), pathogenic Escherichia coli infection (hsa05130,
adjusted p-value = 0.044), Alzheimer’s disease
(hsa05010, adjusted p-value = 0.022), and ribosome
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Gene name Gene Symbol E-value Genebank No. Number of genes
3h 24
ATP synthase F0 subunit 6 ATP6 2.00E-173 XM_002345305 1
28S ribosomal RNA 1.00E-36 NR_003287 3*
B-cell receptor-associated protein 31 BCAP31 0.00E+00 NM_005745 1
calmodulin 2 CALM2 0.00E+00 NM_001743 1
chromosome 6 open reading frame 125 SGA-81M 0.00E+00 NM_032340 1
coiled-coil domain containing 56 CCDC56 0.00E+00 NM_001040431 1
ferritin FTH1 2.00E-30 NM_002032 2*
FSHD region gene 1 family, member B FRG1B 0.00E+00 NR_003579 1
H2A histone family, member Z H2AFZ 8.00E-153 NM_002106 1
H3 histone, family 3A H3F3A 1.00E-163 NM_002107 1
lysosomal protein transmembrane 4 alpha LAPTM4A 0.00E+00 NM_014713 1
mitochondrial ribosomal protein L42 MRPL42 0.00E+00 NM_172178 1
fascin FSCN1 3.00E-29 AAH07539 1
nerve growth factor receptor TNFRSF16 6.00E-142 NM_206915 1
phosphoserine phosphatase PSPH 2.00E-139 NM_004577 1
regulator of G-protein signaling 5 RGS5 0.00E+00 NM_003617 1
small nuclear ribonucleoprotein D3 SNRPD3 0.00E+00 NM_004175 1
superoxide dismutase 1 SOD1 0.00E+00 NM_000454 1
SWI/SNF related, matrix associated, actin dependent regulator of chromatin SMARCE1 0.00E+00 NM_003079 1
ubiquitin C UBC 5.00E-39 NM_021009 1
Unknown genes 1
24 h 47
calcyclin binding protein CACYBP 0.00E+00 NM_014412 1
28S ribosomal RNA 1.00E-36 NR_003287 2*
calmodulin 2 CALM2 0.00E+00 NM_001743 1
casein kinase 1 CSNK1A1 0.00E+00 NM_001892 1
chromosome 14 open reading frame 147 SSSPTA 9.00E-93 NM_138288 1
claudin domain containing 1 CLDND1 0.00E+00 NM_019895 1
early growth response 1 EGR1 0.00E+00 NM_001964 1
ferritin FTL 6.00E-161 NM_000146 1
glutamate-ammonia ligase (glutamine synthetase) GLUL 0.00E+00 NM_002065 3*
glyceraldehyde-3-phosphate dehydrogenase GAPDH 0.00E+00 NM_002046 1
GTP binding protein overexpressed in skeletal muscle GEM 0.00E+00 NM_181702 2*
heat shock 70 kDa protein 8 HSPA8 0.00E+00 NM_006597 1
heat shock protein 90 kDa alpha (cytosolic) HSP90AA1 0.00E+00 NM_005348 1
integrator complex subunit 6 INTS6 0.00E+00 NM_001039937 1
mab-21-like 1 MAB21L1 0.00E+00 NM_005584 1
methionine adenosyltransferase II, beta MAT2B 9.00E-153 NM_182796 1
mitochondrial ribosomal protein L42 MRPL42 0.00E+00 NM_014050 1
NADH dehydrogenase (ubiquinone) 1 NDUFAB1 0.00E+00 NM_005003 1
neurofilament, medium polypeptide NEFM 0.00E+00 NM_005382 1
nudix-type motif 5 NUDT5 0.00E+00 NM_014142 1
pituitary tumor-transforming 1 PTTG1 0.00E+00 NM_004219 1
polo-like kinase 1 PLK1 5.00E-103 NM_005030 1
ribosomal protein L15 RPL15 0.00E+00 NM_002948 1
ribosomal protein L23a RPL23A 0.00E+00 NM_000984 1
RNA binding motif protein 7 RBM7 3.00E-111 NM_016090 1
shisa homolog 2 SHISA2 0.00E+00 NM_001007538 1
cytochrome b CYTB 0.00E+00 XR_078322 1
SNF2 histone linker PHD RING helicase SHPRH 0.00E+00 NM_001042683 1
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of OA come from binding to PP1 and PP2A, a possible
explanation for the altered pathways could be the pro-
tein phosphatases inhibition induced by this toxin. In
fact, inhibition of PP2A by OA has been previously
demonstrated to increase tau phosphorylation, a patho-
logical hallmark of Alzheimer’s disease, in SHSY5Y cells
[48].
Since OA was previously reported to induce several
neurotoxic effects in mammalian cells [20-23] but the
underlying mechanisms are still unknown, five specific
genes associated with important neuronal structures and
f u n c t i o n ss u c ha sc y t o s k e l e ton and neurotransmission,
were selected to confirm their expression levels in
SHSY5Y cells by real-time PCR. Results obtained from
these analyses are shown in Table 4.
NEFM, TUBB2A and SEPT7 expression: OA effects on
neuronal cytoskeleton
The key role of cytoskeletal organization in several
important neural processes such as neurite outgrowth
[49], synaptogenesis [50], structural polarity and neuro-
nal shape [51], axonal transport [52], and neurotrans-
mitter release [53] has been characterized. Cell shape
and structural polarity are lost in neurodegenerative dis-
eases and neural aging [54,55].
OA was previously reported to induce several cytoske-
leton alterations in different cell systems [56,57]. It has
been hypothesized that these alterations could be due to
different mechanisms that involve disruption of F-actin
and ⁄or hyperphosphorylation and activation of kinases
that stimulate tight junction disassembly, but the exact
molecular mechanism has not been elucidated yet [3].
Table 2 cDNAs selected from all 3 forward SHH libraries. (Continued)
TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor TAF9 0.00E+00 NM_003187 1
Tax1 (human T-cell leukemia virus type I) binding protein 1 TAX1BP1 0.00E+00 NM_006024 1
triosephosphate isomerase 1 TPI1 0.00E+00 NM_000365 2*
Unknown genes 11
48 h 43
actin, beta ACTB 0.00E+00 NM_001101 3
adenylate kinase domain containing 1 AKD1 0.00E+00 NM_145025 1
ADP-ribosylation factor-like 6 interacting protein 1 ARL6IP1 0.00E+00 NM_015161 1
CD58 molecule CD58 0.00E+00 NR_026665 1
clusterin CLU 0.00E+00 NM_203339 1
cyclin-dependent kinase inhibitor 1C CDKN1C 0.00E+00 NM_000076 1
cytochrome c oxidase subunit III MT-CO3 6.00E-76 XM_002342023 3*
family with sequence similarity 32 FAM32A 0.00E+00 NM_014077 1
ferritin FTL 0.00E+00 NM_000146 1
glutamate-ammonia ligase GLUL 0.00E+00 NM_002065 1
metallothionein 1X MT1X 2.00E-128 NM_005952 1
metastasis associated lung adenocarcinoma transcript MALAT1 0.00E+00 NR_002819 6*
microtubule-associated protein MAPRE2 0.00E+00 NM_014268 1
M-phase phosphoprotein 8 MPHOSPH8 0.00E+00 NM_017520 1
nudix -type motif 5 NUDT5 0.00E+00 NM_014142 1
prostaglandin reductase 1 PTGR1 0.00E+00 NM_012212 1
serine incorporator 3 SERINC3 0.00E+00 NM_198941 1
cytochrome b CYTB 0.00E+00 XR_078322 1
solute carrier family 25 SLC25A4 0.00E+00 NM_001151 1
S-phase kinase-associated protein 1 SKP1 0.00E+00 NM_170679 1
TIMP metallopeptidase inhibitor 3 TIMP3 3.00E-86 NM_000362 1
transcription elongation factor B (SIII) TCEB1 3.00E-139 NM_005648 1
translocase of outer mitochondrial membrane 5 TOMM5 0.00E+00 NM_001001790 1
tubulin, beta 2C TUBB2C 2.00E-120 NM_006088 1
tubulin, delta 1 TUBD1 2.00E-81 NM_016261 1
tumor necrosis factor, alpha-induced protein 6 TNFAIP6 0.00E+00 NM_007115 1
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein YWHAB 8.00E-110 NM_003404 1
Unknown genes 7
*Only one GenBank identity accession number and the highest Blastp E-value were given here because of the table capacity limitation.
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Gene name Gene Symbol E-value Genebank No. Number of genes
3h 35
ferritin FTL 0.00E+00 NM_000146 1
phosphoglycerate kinase 1 PGK1 0.00E+00 NM_000291 1
SMT3 suppressor of mif two 3 homolog 2 SUMO2 5.00E-115 NM_001005849 1
ribosomal protein S14 RPS14 2.00E-52 NM_001025071 1
ATPase ATP6V0B 1.00E-47 NM_001039457 1
tubulin, beta 2A TUBB2A 2.00E-27 NM_001069 1
actin, beta ACTB 0.00E+00 NM_001101 1
yippee-like 5 YPEL5 3.00E-47 NM_001127401 1
translation elongation factor EEF1A1 0.00E+00 NM_001402 1
early growth response 1 EGR1 0.00E+00 NM_001964 1
glyceraldehyde-3-phosphate dehydrogenase GAPDH 0.00E+00 NM_002046 1
proteasome 26S subunit, ATPase, 5 PSMC5 0.00E+00 NM_002805 1
signal sequence receptor, alpha SSR1 1.00E-130 NM_003144 1
protein disulfide isomerase family A, member 6 PDIA6 0.00E+00 NM_005742 1
malate dehydrogenase MDH1 0.00E+00 NM_005917 2*
ubiquinol-cytochrome c reductase UQCRH 0.00E+00 NM_006004 1
translocase of inner mitochondrial membrane TIMM17A 0.00E+00 NM_006335 1
heat shock 70 kDa protein 8 HSPA8 0.00E+00 NM_006597 2*
peroxiredoxin 3 PRDX3 0.00E+00 NM_006793 1
Sec61 beta subunit SEC61B 0.00E+00 NM_006808 1
CD24 molecule CD24 0.00E+00 NM_013230 1
striatin, calmodulin binding protein 3 STRN3 0.00E+00 NM_014574 1
nucleolar protein 11 NOL11 6.00E-158 NM_015462 1
cleavage and polyadenylation factor subunit PCF11 0.00E+00 NM_015885 1
zinc finger, CCHC domain ZCCHC17 3.00E-138 NM_016505 1
homolog 2, suppressor of mek1 SMEK2 0.00E+00 NM_020463 1
5-azacytidine induced 2 AZI2 2.00E-161 NM_022461 1
anaphase promoting complex subunit 13 ANAPC13 2.00E-94 NR_024401 1
cytochrome c oxidase subunit II MT-CO2 4.00E-150 XR_078889 1
NADH dehydrogenase subunit 4 MT-ND4 7.00E-54 ADG46850 1
Unknown genes 3
24 h 44
cholinergic receptor, nicotinic, alpha 3 CHRNA3 0.00E+00 NM_000743 1
ribosomal protein L3 RPL3 0.00E+00 NM_000967 1
ribosomal protein S6 RPS6 0.00E+00 NM_001010 1
actin, beta ACTB 0.00E+00 NM_001101 1
casein kinase 2 CSNK2B 4.00E-176 NM_001320 1
eukaryotic translation elongation factor 1 alpha 1 EEF1A1 0.00E+00 NM_001402 1
calmodulin 2 CALM2 0.00E+00 NM_001743 4*
septin 7 SEPT7 0.00E+00 NM_001788 1
LIM domain only 1 (rhombotin 1) LMO1 0.00E+00 NM_002315 1
proteasome beta type, 6 PSMB6 0.00E+00 NM_002798 1
signal recognition particle 9 kDa SRP9 0.00E+00 NM_003133 1
translocated promoter region TPR 0.00E+00 NM_003292 1
regulator of G-protein signaling 5 RGS5 0.00E+00 NM_003617 1
NADH dehydrogenase Fe-S protein 2 NDUFS2 0.00E+00 NM_004550 1
myeloid/lymphoid or mixed-lineage leukemia MLLT11 4.00E-143 NM_006818 1
stathmin-like 2 STMN2 0.00E+00 NM_007029 1
component of oligomeric golgi complex 4 COG4 0.00E+00 NM_015386 1
RNA-binding region containing 3 RNPC3 0.00E+00 NM_017619 1
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Page 7 of 14Table 3 cDNAs selected from all 3 reverse SHH libraries. (Continued)
zinc finger, matrin type 5 ZMAT5 0.00E+00 NM_019103 1
synaptotagmin IV SYT4 0.00E+00 NM_020783 2*
non-metastatic cells 1, protein NM23A NM23A 0.00E+00 NM_198175 1
cytochrome c oxidase subunit III MT-CO3 0.00E+00 XM_002342023 4*
ATP synthase F0 subunit 6 MT-ATP6 0.00E+00 XM_002345305 4*
cytochrome c oxidase subunit II MT-CO2 5.00E-149 XR_078889 7*
NADH dehydrogenase subunit 4 MT-ND4 0.00E+00 XR_078993 1
Unknown genes 2
48 h 54
glutathione S-transferase GSTP1 0.00E+00 NM_000852 1
neuropeptide Y NPY 0.00E+00 NM_000905 1
ribosomal protein L3 RPL3 8.00E-120 NM_000967 2*
ribosomal protein L4 RPL4 0.00E+00 NM_000968 1
ribosomal protein L27a RPL27A 0.00E+00 NM_000990 1
ribosomal protein L31 RPL31 1.00E-175 NM_000993 1
ribosomal protein S4 RPS4X 0.00E+00 NM_001007 1
chromosome 5 open reading frame 13 C5orf13 3.00E-85 NM_001142478 1
adenylate kinase 2 AKA2 7.00E-127 NM_001625 1
calmodulin 2 CALM2 0.00E+00 NM_001743 4*
translation initiation factor 4E EIF4E 0.00E+00 NM_001968 1
lactate dehydrogenase B LDHB 0.00E+00 NM_002300 1
NADH dehydrogenase (ubiquinone) 1 NDUFC1 2.00E-100 NM_002494 1
signal recognition particle 9 kDa SRP9 0.00E+00 NM_003133 2*
regulator of G-protein signaling 5 RGS5 2.00E-68 NM_003617 4*
DNAJC25-GNG10 readthrough transcript DNAJC25-GNG10 2.00E-166 NM_004125 1
guanine nucleotide binding protein G protein 0.00E+00 NM_004126 1
sperm associated antigen 7 SPAG7 0.00E+00 NM_004890 1
heat shock protein 90 kDa HSP90AA1 2.00E-166 NM_005348 1
chaperonin containing TCP1, subunit 3 CCT3 0.00E+00 NM_005998 1
ATP synthase ATP5L 9.00E-140 NM_006476 1
mortality factor 4 like 1 MORF4L1 5.00E-96 NM_006791 1
myeloid/lymphoid or mixed-lineage leukemia MLLT11 0.00E+00 NM_006818 1
transmembrane emp24-like trafficking protein TMED10 0.00E+00 NM_006827 1
dickkopf homolog 1 DKK1 4.00E-70 NM_012242 1
signal peptidase complex subunit 1 SPCS1 0.00E+00 NM_014041 1
mitochondrial ribosomal protein L42 MRPL42 5.00E-142 NM_014050 1
HIG1 hypoxia inducible domain family HIGD1A 0.00E+00 NM_014056 1
signal peptidase complex subunit 2 SPCS2 0.00E+00 NM_014752 1
mitochondrial ribosomal protein S7 MRPS7 4.00E-156 NM_015971 1
splicing factor 3B SF3B14 0.00E+00 NM_016047 1
hematological and neurological expressed 1 HN1 5.00E-168 NM_016185 1
transmembrane protein 9 TMEM9 0.00E+00 NM_016456 1
chromosome 20 open reading frame 3 APMAP 0.00E+00 NM_020531 1
synaptotagmin IV SYT4 0.00E+00 NM_020783 1
ribosomal protein L41 RPL41 0.00E+00 NM_021104 1
transmembrane protein 167A TMEM167A 0.00E+00 NM_174909 1
tubulin, beta TUBB 6.00E-101 NM_178014 1
THAP domain containing 5 THAP5 6.00E-154 NM_182529 1
K(lysine) acetyltransferase 5 KAT5 0.00E+00 NM_182709 1
gonadotropin-releasing hormone GNRHR2 0.00E+00 NR_002328 1
cytochrome c oxidase subunit II MT-CO2 1.00E-151 XR_078889 1
Unknown genes 4
*Only one GenBank identity accession number and the highest Blastp E-value were given here because of the table capacity limitation.
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Page 8 of 14The cytoskeleton is made up of three kinds of protein
filaments: actin filaments (also called microfilaments),
intermediate filaments (IF) and microtubules, and other
associated proteins. NEFM is the human gene which
encodes for the neurofilament medium polypeptide.
Neurofilaments (NEFs) are a neuron-specific type of
intermediate filament proteins (10 nm in diameter)
found at especially high concentrations along the axons,
w h e r et h e yr e g u l a t ea x o n a ld i a m e t e r .N E F sc o n s i s to f
three proteins according to their molecular weight: light
neurofilament (NEFL), medium neurofilament (NEFM),
and heavy neurofilament (NEFH) [58]. NEFM gene is
often employed as a marker of neuronal differentiation
[59]. NEF protein levels are correlative to neurite out-
growth, and its gene expression is dramatically altered
in neurodegenerative diseases, including Parkinson’s dis-
ease and Alzheimer’s disease [60]. NEF protein levels
have also been suggested as a potential biomarker in
organophosphorous neurotoxicity [36]. Furthermore,
neurite outgrowth can be promoted by nerve growth
factor (NGF) via the regulation of NEF gene expression
and NEF protein phosphorylation [61]. In the present
study a statistically significant underexpression of this
gene was found after 3 h OA treatment, but an overex-
pression was observed after 24 h, and no effects after 48
h, suggesting that OA deregulates NEFM expression at
the short term (within at least the first 24 h), but then it
stabilizes and return to control levels. It was previously
described that tight coordination of the expression of
neurofilament subunits is integral to the normal
development and function of the nervous system. Imbal-
ances in their expression are implicated in the induction
of neurodegeneration in which formation of neurofila-
mentous aggregates is central to the pathology [62]. To
our knowledge, no studies were reported before on the
expression of this gene in human neuronal cells exposed
to OA; nevertheless incubation of human fibroblasts
[63] or rat brain tumour cells [64] with OA promoted
the hyperphosphorylation of major intermediate fila-
ments (IF) proteins, leading to the disassembly of IF
networks, solubilisation of IF proteins, and disruption of
desmosomes.
Microtubules are involved in many cellular functions,
including mitosis, intracellular transport, determination
of cell morphology, and differentiation [65]. In neurons,
microtubules participate actively in the initial steps of
neuronal polarization, the organization of intracellular
compartments, the modelling of dendritic spines and
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Table 4 Gene expression after real-time PCR.
Control OA (100 nM)
3 h treatment
NEFM 0.7 ± 0.1 0.1 ± 0.0*
TUBB 1.6 ± 0.4 1.0 ± 0.4
SEPT7 1.7 ± 0.4 1.0 ± 0.1*
SYT4 1.4 ± 0.0 0.3 ± 0.0**
NPY 0.6 ± 0.2 0.3 ± 0.0*
24 h treatment
NEFM 1.6 ± 0.0 5.6 ± 0.6*
TUBB 1.5 ± 0.1 0.4 ± 0.0**
SEPT7 1.2 ± 0.1 0.9 ± 0.2
SYT4 2.8 ± 0.1 0.7 ± 0.2*
NPY 2.3 ± 0.3 1.3 ± 0.1*
48 h treatment
NEFM 1.3 ± 0.1 0.8 ± 0.3
TUBB 1.3 ± 0.1 1.5 ± 0.7
SEPT7 0.6 ± 0.0 0.7 ± 0.0
SYT4 0.9 ± 0.1 0.9 ± 0.0
NPY 1.1 ± 0.1 1.2 ± 0.1
*P < 0.05, **P < 0.01, significant difference with regard to the expression of
reference gen.
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Page 9 of 14the trafficking of cargo molecules to pre-, post- or extra-
synaptic domains [66]. Tubulin, the subunit protein of
microtubules, is a heterodimer, with both a-a n db-
tubulin isotypes, differing from each other in amino acid
sequence [67]. In our study, the expression levels of
TUBB2A, the gene encoding for the tubulin b chain 2A,
were analyzed in OA-treated neuronal cells. Data
obtained from the real-time PCR analysis showed that
this gene is down-regulated in OA-treated SHSY5Y cells
at 3 h and 24 h, significantly only in the second case,
but at 48 h its expression levels were not different from
the control. Microtubules were found to be altered after
OA exposure in some previous studies mainly due to
the hyperphosphorilation of tau, a microtubule-asso-
ciated protein which promotes microtubule enlarge-
ment. Inhibition of PP2A activity by OA was suggested
to produce the abnormal tau hyperphosphorylation in
vivo after hippocampal injection in rats [68] and in vitro
in metabolically competent brain rats [69], in mouse
hippocampal HT22 cell line [70] and in human neuronal
NT2N and SHSY5Y cells [48,71]. Besides, Yano et al.
[56] found that OA induces reorganization of microtu-
bules in human platelets via the phosphorylation of a
microtubule-associated 90 kDa protein, and Benitez-
King et al. [72] showed that OA produces cytoskeletal
disorganization and microtubule disruption in N1E-115
neuroblastoma cells, as described in other neuronal cell
culture models and in rat brain [20,73,74]. TUBB2A was
characterized primarily as a neuronal b-tubulin isotype
[75] and possess a high expression level in brain, periph-
eral nerves and muscles [76]. Tubulin isotype composi-
tion may be a determinant factor on microtubule
functions. Therefore, changes in expression levels of
tubulin subtypes would alter the microtubule dynamics.
In this sense, Falconer et al. [77] demonstrated that
TUBB2 is preferentially incorporated into stable micro-
tubules during neuronal differentiation, and Hoffman
and Cleveland [78] reported that the isotype TUBB2 is
polymerized more efficiently than other isotypes. The
higher expression observed in several types of tumours
[79] and in cancer cells resistant to microtubule-binding
drugs [80] could be related with the more stability of
TUBB2A isotype. The underexpression of TUBB2A
observed in this work might contribute to cytoskeletal
disruption effects of OA in a similar way, since the
major isotype in neuronal cells and the more would be
incorporated in a lesser extent to microtubules of
SHSY5Y OA-exposed cells.
Septins are an evolutionarily conserved family of
cytoskeleton GTP-binding proteins [81]. They play puta-
tive roles in cytokinesis, cellular morphogenesis, polarity
determination, vesicle trafficking and apoptosis [82-85].
Septins have been identified in all eukaryotic cells.
Although yeast septins are better understood, the
function of mammalian septins remains largely unde-
fined [86]. SEPT7 is a member of the septin family
which is abundantly expressed in the central nervous
system [81], but its functional role has not been
reported yet [87]. However, a previous study showed
that SEPT7 is critical for spine morphogenesis and den-
drite development during neuronal maturation [87] and
other study confirmed that SEPT7 directly interacts with
CENP-E via the C-terminal coiled-coil region. This
SEPT7-CENP-E interaction is critical for a stable CENP-
E localization to the kinetochore and for achieving chro-
mosome alignment at the equator [88]. SEPT7 has been
also related to oncogenesis. After investigating SEPT7
expression in a large number of human glioma tissue
samples, Jia et al. [86] found that the expression of this
gene was generally down-regulated in gliomas or even
absent in some high-grade tumours. Furthermore, they
showed that SEPT7 induces cell apoptosis through
down-regulation of Bcl-2 and up-regulation of caspase-
3, and increased cell apoptosis also contributes to the
inhibitory effect of SEPT7 on glioma cell growth. Other
studies showed that SEPT7 was much less expressed in
brain tumours than in normal brain tissues [81,89] and
that neuroblastoma patients with higher SEPT7 mRNA
expression might have better prognosis [90]. In our
study a significant decrease in the SEPT7 expression
levels were found at 3 h, however no differences with
regard to the control cells were observed after 24 or 48
h OA treatment.
Therefore, the results obtained from the genes related
to cytoskeleton evaluated in this study suggest that the
cytoskeleton disruption induced by OA described in
previous works are due not only to the hyperphosphory-
lation of specific proteins caused by phosphatases inhibi-
tion, but also to short term alterations (mainly down-
regulation) in the expression levels of relevant genes
involved in the maintenance of the cell structure as the
TUBB2A, NEFM or SEPT7 genes. The fact that no
effects of OA were observed after 48 h treatment in any
of these genes could be related to cells ability to recover
and return to their normal expression levels. However,
cell viability was enormously reduced after 48 h OA
treatment (microscopic observations). Thus, the absence
of gene expression alterations found at that time might
also be due to the fact that those cells intensely altered
by OA in their gene expression at 3 and 24 h treatments
underwent apoptosis or necrosis, being absent at 48 h.
SYT4 and NPY expression: OA effects on synaptic
neurotransmission
Synaptic neurotransmission is one of the most highly
regulated of all vesicle trafficking events. Although many
of the molecular components of synaptic vesicles, the
presynaptic cytosol, and presynaptic plasma membrane
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Page 10 of 14have been identified, the mechanisms by which these
components regulate stimulus evoked vesicle fusion and
recycling are not completely understood yet. In this
study, expression levels of two genes related to the neu-
ronal signal transduction (SYT4 and NPY) after OA
exposure were investigated.
The synaptotagmins (SYTs) are a family of proteins
characterized by a short luminal NH2 terminus, one
transmembrane region, and tandem C2A and C2B
domains [91]. These synaptic proteins are also impor-
tant in depolarization-induced, Ca
2+-dependent fusion
of the synaptic vesicles and presynaptic membrane [92].
Currently, it is thought that SYTs participate in the reg-
ulation of various steps during membrane fusion, pri-
marily at the plasma membrane [93]. There are at least
17 SYTs isoforms that have the potential to act as mod-
ulators of membrane fusion events. SYT4 is particularly
interesting since it has been found to be potentially
involved in a wide variety of activities in the brain [94];
it is an immediate early gene that is up-regulated follow-
ing neuronal depolarization [95] and maps to a region of
human chromosome 18 associated with schizophrenia
and bipolar disease [96]. Data obtained from real-time
PCR showed that the SYT4 expression is inhibited by
OA at 3 and 24 h exposure, but it recovers normal
levels at 48 h treatment. In a previous study, loss of
SYT4 results in a reduction of synaptic vesicles and a
distortion of the Golgi structure in cultured hippocam-
pal neurons [94]. Golgi disruptions were also found in
rat pancreatic cells after OA exposure [45]. Besides,
SYT4 affects a number of vesicle recycling properties in
peptidergic nerve terminals in the posterior pituitary
[97]. Interestingly, SYT4 also appears to play a role in
the maturation of secretory granules in neuroendocrine
cells [93], suggesting that it may also function in the
movement of vesicles [91].
Neuropeptide Y (NPY) is a 36-amino acid peptide
produced by neurons throughout the brain and by other
secretor cells of the body. NPY has been associated with
a number of physiological processes in the brain, includ-
ing the regulation of energy balance, memory and learn-
ing, and epilepsy [98]. Similarly to SYT4, NPY
expression levels after OA exposure were found to be
down-regulated at 3 and 24 h, but expression levels
similar to control were observed at 48 h. A deregulation
of the hypothalamic NPY system has been proposed to
be related to several pathological and pathophysiological
states including cancer cachexia [99], hyperinsulinemia
and hypercorticism [100], obesity and metabolic syn-
drome [101], and anorexia [102].
So far, no studies on SYT4 or NYP expression after
OA exposure were reported, but several previous studies
described neurotransmission alterations after OA expo-
sure, and the down-regulation of genes involved in the
synaptic processes found in this study could help to
explain them. OA was found to inhibit mobilization of
synaptic vesicles and depress Ca
2+ release from sarco-
plasmic reticulum in mouse neuromuscular junctions
[103], to disrupt synaptic vesicle trafficking in goldfish
bipolar cells [104], and to interfere with the formation
of synaptic vesicle clusters in nerve terminals of frog
neuromuscular junctions [105]. In vivo, OA significantly
reduces electrically induced inhibitory non-adrenergic,
non-cholinergic (NANC) neurotransmission responses
in the rat gastric fundus, while leaving direct muscular
effects of the inhibitory NANC neurotransmitters
vasoactive intestinal peptide and nitric oxide unaffected,
suggesting a neural site of action [106]. It was also
reported that presynaptic clusters of synaptic vesicles at
the frog neuromuscular junction can be disrupted by
exposure to OA [105]. Furthermore, our data involving
genes related to neurotransmission could also underlie
the OA effects previously reported on the rodent ner-
vous system in vivo such as hyperexcitation [107], spa-
tial memory deficit and neurodegeneration [22] and
cognitive deficits [48]. Similarly to the results obtained
for the cytoskeleton genes expression, the expression
levels of both SYT4 and NPY were highly depressed at 3
and 24 h OA exposure, but they went back to basal
levels after 48 h, suggesting that surviving cells were
able to recover from OA-induced gene expression
alterations.
Conclusions
To elucidate the molecular mechanisms involved in the
OA-induced neurotoxic effects, SSH was used in
SHSY5Y cells to identify genes with altered expression
level at designated treatment times in the promotion
stage, including an early time point (3 h), a middle time
point (24 h) and a late time point (48 h). A total of 247
known genes were found to be altered. At 3 h OA treat-
ment genes altered are mainly involved in metabolism,
including electron transport chain and transcription
processes. At 24 and 48 h OA treatments, the percen-
tage of genes related to translation, cell cycle and apop-
tosis increased. The percentage of genes related to
signal transduction, cytoskeleton and metabolism was in
general constant at the 3 treatment times.
The data obtained from SHH were confirmed by real-
time PCR for 5 specific genes associated with neuronal
cytoskeleton and neurotransmission: NEFM, TUBB2A,
SEPT7, SYN4, and NPY. The expression levels of the
three genes involved in cytoskeleton processes (NEFM,
TUBB2A and SEPT7) were found to be altered at 3 and
24 h OA treatments. These alterations could help to
explain the previously reported cytoskeleton modifica-
tions induced by OA including cell rounding, loss of sta-
bilization of focal adhesions, loss of barrier properties,
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Page 11 of 14and loss of cell polarity [56,57,108-110]. The down-regu-
lation observed at the short term (3 and 24 h) of the
two genes participating in synaptic neurotransmission
(SYT4 and NPY), might be the basis of several reported
OA-induced neurotoxic effects [22,48,107]. No expres-
sion alterations were observed for any of the five studied
genes at 48 h OA exposure, so surviving cells recovered
their normal gene expression levels. In order to test
whether current results are dependent on OA dose,
similar experiments testing different OA concentrations
are currently being carried out. Further investigations
on the expression patterns of other relevant genes is
required in order to completely understand the different
effects induced by OA in these and other cells.
Additional material
Additional file 1: Single gene set enrichment analysis (KEGG
pathways) of genes from forward libraries. Excel spreadsheet showing
the results obtained from FatiGO analysis of the genes upregulated in
SSH.
Additional file 2: Single gene set enrichment analysis (KEGG
pathways) of genes from reverse libraries. Excel spreadsheet showing
the results obtained from FatiGO analysis of the genes downregulated in
SSH.
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